skip to content
Thank you for visiting First Coast Service Options' Medicare provider website. This website is intended exclusively for Medicare providers and health care industry professionals to find the latest Medicare news and information affecting the provider community.
To enable us to present you with customized content that focuses on your area of interest, please select your preferences below:
Select which best describes you:
Select your location:
Select your line of business:

Disclaimer

LICENSE FOR USE OF "PHYSICIAN'S CURRENT PROCEDURAL TERMINOLOGY" (CPT), FOURTH EDITION End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2022 American Medical Association (AMA).

All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.
You, your employees, and agents are authorized to use CPT only as contained in the following authorized materials:
Local Coverage Determinations (LCDs),
Local Medical Review Policies (LMRPs),
Bulletins/Newsletters,
Program Memoranda and Billing Instructions,
Coverage and Coding Policies,
Program Integrity Bulletins and Information,
Educational/Training Materials,
Special mailings,
Fee Schedules;

internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare and Medicaid Services (CMS), formerly known as Health Care Financing Administration (HCFA). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA website. Applicable FARS/DFARS restrictions apply to government use.

AMA Disclaimer of Warranties and LiabilitiesCPT is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this agreement.

CMS DisclaimerThe scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

AMA - U.S. Government Rights

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a )June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

ADA CURRENT DENTAL TERMINOLOGY, (CDT)
End User/Point and Click Agreement: These materials contain Current Dental Terminology (CDTTM), Copyright © 2016 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING ON THE BUTTON LABELED "ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK ON THE BUTTON LABELED "DECLINE" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the ADA website.

Applicable Federal Acquisition Regulation Clauses (FARS)\Department of restrictions apply to Government Use.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES: CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third party beneficiary to this Agreement.

CMS DISCLAIMER: The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

End Disclaimer



This website provides information and news about the Medicare program for health care professionals only. All communication and issues regarding your Medicare benefits are handled directly by Medicare and not through this website. For the most comprehensive experience, we encourage you to visit Medicare.gov or call 1-800-MEDICARE. In the event your provider fails to submit your Medicare claim, please view these resources for claim assistance.
Join eNews       En Español
Text Size:
YouTube LinkedIn Email Print
Send a link to this page
[Multiple email adresses must be separated by a semicolon.]
Last Modified: 12/29/2022 Location: FL, PR, USVI Business: Part B

COVID-19 vaccine and monoclonal antibody billing for Part B providers

This article will assist Medicare Part B providers with proper billing relating to Coronavirus (COVID-19) vaccine and monoclonal antibody (mAb) infusion. Beneficiary coinsurance and deductible are waived.

How to bill for COVID-19 vaccines and monoclonal antibodies

For billing single claims for COVID-19 vaccines and monoclonal antibodies, follow the instructions in the article below.
For roster billing and centralized billing refer to the Medicare billing for COVID-19 vaccine shot administration external link page.
When COVID-19 vaccine and monoclonal antibody doses are provided by the government without charge, only bill for the vaccine administration. Don't include the vaccine codes on the claim when the vaccines are free.
If the patient is enrolled in a Medicare Advantage (MA) plan, submit your COVID-19 vaccine and monoclonal antibody infusion claims to Original Medicare in 2020 and 2021. On or after January 1, 2022, claims for vaccine or mAb administrations for Medicare Advantage enrollees should be submitted to the Medicare Advantage plan. For services provided to Medicare Advantage enrollees on or after January 1, 2022, contact the Medicare Advantage for guidance on coverage and billing.

COVID-19 vaccines and administration

Code
Description
Labeler name
Vaccine/procedure name***
Effective date
91300*
SARSCOV2 VAC 30MCG/0.3ML IM
Pfizer
Pfizer-BioNTech COVID-19 Vaccine (Aged 12 years and older) (Purple Cap)
12/11/2020
0001A
ADM SARSCOV2 30MCG/0.3ML 1ST
Pfizer
Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – First Dose
12/11/2020
0002A
ADM SARSCOV2 30MCG/0.3ML 2ND
Pfizer
Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – Second Dose
12/11/2020
0003A
ADM SARSCOV2 30MCG/0.3ML 3RD
Pfizer
Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – Third Dose
08/12/2021
0004A
ADM SARSCOV2 30MCG/0.3ML BST
Pfizer
Pfizer-BioNTech COVID-19 Vaccine (Purple Cap) Administration – Booster
09/22/2021
91301*
SARSCOV2 VAC 100MCG/0.5ML IM
Moderna
Moderna COVID-19 Vaccine (Aged 12 years and older) (Red Cap)
12/18/2020
0011A
ADM SARSCOV2 100MCG/0.5ML1ST
Moderna
Moderna COVID-19 Vaccine (Red Cap) Administration – First Dose
12/18/2020
0012A
ADM SARSCOV2 100MCG/0.5ML2ND
Moderna
Moderna COVID-19 Vaccine (Red Cap) Administration – Second Dose
12/18/2020
0013A
ADM SARSCOV2 100MCG/0.5ML3RD
Moderna
Moderna COVID-19 Vaccine (Red Cap) Administration – Third Dose
08/12/2021
91303*
SARSCOV2 VAC AD26 .5ML IM
Janssen
Janssen COVID-19 Vaccine (Aged 18 years and older)
02/27/2021
0031A
ADM SARSCOV2 VAC AD26 .5ML
Janssen
Janssen COVID-19 Vaccine Administration – First Dose
02/27/2021
0034A
ADM SARSCOV2 VAC AD26 .5ML B
Janssen
Janssen COVID-19 Vaccine Administration - Booster
10/20/2021
0044A
ADM SARSCOV2 5MCG/0.5ML BST
Novavax
Novavax COVID-19 Vaccine Administration - Booster
10/19/2022
91304*
SARSCOV2 VAC 5MCG/0.5ML IM
Novavax
Novavax COVID-19 Vaccine, Adjuvanted (Aged 12 years and older)
07/13/2022
0041A
ADM SARSCOV2 5MCG/0.5ML 1ST
Novavax
Novavax COVID-19 Vaccine, Adjuvanted Administration – First Dose
07/13/2022
0042A
ADM SARSCOV2 5MCG/0.5ML 2ND
Novavax
Novavax COVID-19 Vaccine, Adjuvanted Administration – Second Dose
07/13/2022
91305*
SARSCOV2 VAC 30 MCG TRS-SUCR
Pfizer
Pfizer-BioNTech Covid-19 Vaccine Pre-Diluted (Aged 12 years and older) (Gray Cap)
01/03/2022
0051A
ADM SARSCV2 30MCG TRS-SUCR 1
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - First dose
01/03/2022
0052A
ADM SARSCV2 30MCG TRS-SUCR 2
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Second dose
01/03/2022
0053A
ADM SARSCV2 30MCG TRS-SUCR 3
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Third dose
01/03/2022
0054A
ADM SARSCV2 30MCG TRS-SUCR B
Pfizer
Pfizer-BioNTech COVID-19 Vaccine Pre-Diluted (Gray Cap) Administration - Booster
01/03/2022
91306*
SARSCOV2 VAC 50MCG/0.25ML IM
Moderna
Moderna COVID-19 Vaccine (Aged 18 years and older) (Red Cap) (Low Dose)
10/20/2021
0064A
ADM SARSCOV2 50MCG/0.25MLBST
Moderna
Moderna COVID-19 Vaccine (Low Dose) Administration - Booster
10/20/2021
91307*
SARSCOV2 VAC 10 MCG TRS-SUCR
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 5 years through 11 years) (Orange Cap)
10/29/2021
0071A
ADM SARSCV2 10MCG TRS-SUCR 1
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - First dose
10/29/2021
0072A
ADM SARSCV2 10MCG TRS-SUCR 2
Pfizer
Pfizer-BioNTech Covid-19 Pediatric Vaccine (Orange Cap) - Administration - Second dose
10/29/2021
0073A
ADM SARSCV2 10MCG TRS-SUCR 3
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - Third dose
01/03/2022
0074A
ADM SARSCV2 10MCG TRS-SUCR B
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Orange Cap) - Administration - Booster
05/17/2022
91308*
SARSCOV2 VAC 3MCG TRS-SUCR
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap)
06/17/2022
0081A
ADM SARSCOV2 3MCG TRS-SUCR 1
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - First dose
06/17/2022
0082A
ADM SARSCOV2 3MCG TRS-SUCR 2
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - Second dose
06/17/2022
0083A
ADM SARSCOV2 3MCG TRS-SUCR 3
Pfizer
Pfizer-BioNTech COVID-19 Pediatric Vaccine (Aged 6 months through 4 years) (Maroon Cap) - Administration - Third dose
06/17/2022
91309*
SARSCOV2 VAC 50MCG/0.5ML IM
Moderna
Moderna COVID-19 Vaccine (Aged 6 years through 11 years or aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML
03/29/2022
0091A
ADM SARSCOV2 50 MCG/.5 ML1ST
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - First dose
06/17/2022
0092A
ADM SARSCOV2 50 MCG/.5 ML2ND
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - Second dose
06/17/2022
0093A
ADM SARSCOV2 50 MCG/.5 ML3RD
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 years through 11 years) (Blue Cap with purple border) - Administration - Third dose
06/17/2022
0094A
ADM SARSCOV2 50MCG/0.5 MLBST
Moderna
Moderna COVID-19 Vaccine (Aged 18 years and older) (Blue Cap with purple border) 50MCG/0.5ML Administration - Booster
03/29/2022
91311*
SARSCOV2 VAC 25MCG/0.25ML IM
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) 250MCG/0.25ML
06/17/2022
0111A
ADM SARSCOV2 25MCG/0.25ML1ST
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) - Administration - First dose
06/17/2022
0112A
ADM SARSCOV2 25MCG/0.25ML2ND
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) - Administration - Second dose
06/17/2022
0113A
ADM SARSCOV2 25MCG/0.25ML3RD
Moderna
Moderna COVID-19 Pediatric Vaccine (Aged 6 months through 5 years) (Blue Cap with magenta border) - Administration - Third dose
06/17/2022
91312
SARSCOV2 VAC BVL 30MCG/0.3M
Pfizer
Pfizer-BioNTech COVID-19 Vaccine, Bivalent Product (Aged 12 years and older) (Gray Cap)
08/31/2022
0124A
ADM SARSCV2 BVL 30MCG/.3ML B
Pfizer
Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Gray Cap) Administration – Booster Dose
08/31/2022
91313
SARSCOV2 VAC BVL 50MCG/0.5ML
Moderna
Moderna COVID-19 Vaccine, Bivalent Product (Aged 18 years and older) (Dark Blue Cap with gray border)
08/31/2022
0134A
ADM SARSCV2 BVL 50MCG/.5ML B
Moderna
Moderna COVID-19 Vaccine, Bivalent (Aged 18 years and older) (Dark Blue Cap with gray border) Administration – Booster Dose
08/31/2022
91314
SARSCOV2 VAC BVL 25MCG/.25ML
Moderna
Moderna COVID-19 Vaccine, Bivalent product
10/12/2022
0144A
COVID-19 Vaccine, Bivalent - Administration
Moderna
Moderna COVID-19 Vaccine, Bivalent - Administration – Booster Dose
10/12/2022
91315
SARSCOV2 VAC BVL 10MCG/0.2ML
Pfizer
Pfizer-BioNTech COVID-19 Vaccine, Bivalent product
10/12/2022
0154A
COVID-19 Vaccine, Bivalent - Administration
Pfizer
Pfizer COVID-19 Vaccine, Bivalent - Administration – Booster Dose
10/12/2022
91316
SARSCOV2 VAC BVL 10MCG/0.2ML
Moderna
Moderna COVID-19 Vaccine, Bivalent for use as a booster for ages 6 months through 5 years
12/08/2022
0164A
COVID-19 Vaccine, Bivalent Administration
Moderna
Moderna COVID-19 Vaccine, Bivalent Administration for use as a booster for ages 6 months through 5 years
12/08/2022
91317
SARSCOV2 VAC BVL 3MCG/0.2ML
Pfizer
Pfizer-BioNTech COVID-19 Vaccine, Bivalent for use as a third primary series dose for ages 6 months through 4 years
12/08/2022
0173A
COVID-19 Vaccine, Bivalent Administration
Pfizer
Pfizer-BioNTech COVID-19 Vaccine, Bivalent administration for use as a third primary series dose for ages 6 months through 4 years
12/08/2022
M0201**
COVID-19 vaccine home admin
N/A
COVID-19 vaccine administration inside a patient’s home; reported only once per individual home per date of service when only COVID-19 vaccine administration is performed at the patient’s home
06/08/2021
*Providers should not bill for the product if they received it for free.
**Billable only in places of service 04, 06, 09, 12, 13, 14, 16, 19, 22, 33, 54, 55, 56, and 60. For additional billing information on M0201, review CMS’ infographic on Medicare payment for COVID-19 vaccine administration in the home external pdf file.
***For information on dosing intervals, refer to the CDC article U.S. COVID-19 Vaccine Product Information external link.
Providers can submit claims using the following claim example:
Claim should include the proper billing of the ICD-10 in item 21:
Z23 - Encounter for immunization
Report the proper date of service
Report the proper place of service
Use the applicable CPT or HCPCs code
The diagnosis pointer should be used to indicate the primary diagnosis on the claim form
Claim example 1

Monoclonal antibodies and administration

Code
Description
Labeler name
Vaccine/procedure name
Effective date
Q0220*
Tixagev and cilgav, 300mg
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg
12/08/2021
Q0221*
Tixagev and cilgav, 600mg
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg
02/24/2022
M0220
Tixagev and cilgav inj
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring
12/08/2021
M0221
Tixagev and cilgav inj hm
AstraZeneca
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
12/08/2021
Q0222***
Bebtelovimab 175 mg
Eli Lilly
Injection, bebtelovimab, 175 mg
02/11/2022
M0222
Bebtelovimab injection
Eli Lilly
Intravenous injection, bebtelovimab, includes injection and post administration monitoring
02/11/2022
M0223
Bebtelovimab injection home
Eli Lilly
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
02/11/2022
Q0239*
bamlanivimab-xxxx
Eli Lilly
Injection, bamlanivimab, 700 mg
11/10/2020 – 04/16/2021
M0239
bamlanivimab-xxxx infusion
Eli Lilly
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
11/10/2020 – 04/16/2021
Q0240*
Casirivi and imdevi 600mg
Regeneron
Injection, casirivimab and imdevimab, 600 mg
07/30/2021
M0240
Casiri and imdev repeat
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
07/30/2021
M0241
Casiri and imdev repeat hm
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses
07/30/2021
Q0243*
casirivimab and imdevimab
Regeneron
Injection, casirivimab and imdevimab, 2400 mg
11/21/2020
M0243
Casirivi and imdevi inj
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring
11/21/2020
Q0244*
casirivi and imdevi 1200 mg
Regeneron
Injection, casirivimab and imdevimab, 1200 mg
06/03/2021
M0244
Casirivi and imdevi inj hm
Regeneron
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/06/2021
Q0245*
bamlanivimab and etesevima
Eli Lilly
Injection, bamlanivimab and etesevimab, 2100 mg
02/09/2021
M0245
bamlan and etesev infusion
Eli Lilly
intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
02/09/2021
M0246
bamlan and etesev infus home
Eli Lilly
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/06/2021
Q0247**
sotrovimab
GSK
Injection, sotrovimab, 500 mg
05/26/2021
M0247
sotrovimab infusion
GSK
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
05/26/2021
M0248
sotrovimab inf, home admin
GSK
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
05/26/2021
Q0249**
Tocilizumab for COVID-19
Genentech
Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
06/24/2021
M0249
Adm Tocilizu COVID-19 1st
Genentech
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose
06/24/2021
M0250
Adm Tocilizu COVID-19 2nd
Genentech
Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose
06/24/2021
*Providers should not bill for the product if they received it for free.
**The government won’t provide this drug for free.
***Q0222 – Eli Lilly started commercial distribution on August 15. For dates of service on or after August 15, claims for commercially acquired treatments may be allowed at the new payment rate of $2,394.00. You may have supplies of both the United States Government (USG)-procured and commercially procured product. Providers should only bill above a nominal amount for the commercially procured product. You can identify the commercially procured vials by the batch number D534422 and other batch numbers will be issued. Review the batch number prior to claim submission to determine if the product was USG procured or commercially procured and ensure appropriate billing.
Providers can submit claims using the following claim example:
Claim should include the proper billing of the ICD-10 in item 21:
Use appropriate diagnosis coded to highest level of specificity
U071 – use as appropriate
Report the proper date of service
Report the proper place of service
Use the applicable CPT or HCPCs code
The diagnosis pointer should be used to indicate the primary diagnosis on the claim form
Report the charge amount for each line item
laim example 2
Click here for information on billing these services through roster billing.

References

FDA: COVID-19 Vaccines external link webpage
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.